EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
about
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesIntravesical chemotherapy in non-muscle-invasive bladder cancerApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyThe Yin and Yang of Toll-like receptors in cancerDiagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysisOptical coherence tomography diagnostics for onco-urology. Review of clinical perspectives.Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineUreteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic reviewBladder cancer biomarker discovery using global metabolomic profiling of urineUltrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approachBladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov.Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma.Significance of random bladder biopsies in non-muscle invasive bladder cancer.MicroRNAs as biomarkers associated with bladder cancer.Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinomaPrognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladderMicroRNAs in biofluids are novel tools for bladder cancer screening.Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinRobot-assisted radical cystectomy with intracorporeal neobladder diversion: The Karolinska experience.Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection.Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort studyHigh expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the BladderValproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression.Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylationThe 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancerDNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancerClinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.Detection of microRNAs in archival cytology urine smears.P53 and cancer-associated sialylated glycans are surrogate markers of cancerization of the bladder associated with Schistosoma haematobium infection.Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studiesA pilot study combining a GC-sensor device with a statistical model for the identification of bladder cancer from urine headspace.Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosisTherapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trialsIncreased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide.
P2860
Q26775541-7AA3EFAF-92F3-4973-B789-BF4492B42185Q26775982-2580950B-7AAE-4F0B-8638-8A4D4629B4CAQ26798372-15FFE7E4-D619-483F-B423-CD3D01F624DFQ26851526-87779B61-5BDF-404A-9AC3-C62B293EF26DQ26859123-EFA1D21A-0A63-41C5-8FF1-7DB275DAE22DQ27002461-9444359F-4798-407B-B863-90750B85C8F4Q27006765-C9723C4C-C791-4308-AC5C-7E59D9CBD9DFQ27027783-70C4A977-690F-450B-B155-56562370BFA6Q28542873-431555E3-5B0D-43ED-B0CA-4909DDE2C70DQ30455697-AC0E7046-50F7-4B5E-89DD-25EBEA3440A7Q30683510-70981140-F752-42EC-B1F4-CA3410AE60CCQ30839472-84206432-3B9E-4177-A79F-1EC3C00116E6Q33597571-79FFA5DC-9833-4325-A480-6CA3FDBD80F4Q33642335-E8F360D0-07BD-450D-BA2B-D19F705DF125Q33686437-BC80E15E-426D-4FFA-9652-245BCB8BDFEBQ33733739-78617556-585D-4C8F-9EA8-DD89BDDFBF23Q33762123-6596C151-B5CF-4FE7-BFE9-8814E34FA940Q33917646-AF688BE5-5804-43F4-AABA-1E3D8DBCD4B1Q33962426-F15EB2BC-DE78-406C-BA91-3253FC978935Q33995446-877D1EF3-56C1-4573-AA67-894C85C389BAQ34026715-D0A3590D-4625-4E12-AAE6-5DAE528AB4C2Q34075838-66299A22-CF57-4CE1-97EA-6FCFD42B957BQ34147692-C3C99066-06BC-410B-B014-9EE37E66189BQ34171782-A3D10B57-7DA6-47AC-9F61-E08DAB222575Q34183647-F4F89994-251C-4CC1-B452-A7A99B82A706Q34184763-3B6CC918-29B5-4D72-B007-A6DA8E55E28EQ34279215-1521088A-3123-4C70-8705-58A2A62E9680Q34381913-01462A52-3B5D-4ECC-81A8-AC969A838F86Q34441297-44D703A3-3FF8-4FE7-97EC-EB27DAA83506Q34452006-A5F3B114-63CE-4EFA-94E1-846CB9BBADE2Q34463194-BA46D0A9-2BFC-452A-A79C-DD048C310674Q34515117-F30C0721-FF97-4748-81E8-A19092826B1CQ34544542-B775C103-E678-44F0-BAD5-58CBB89730CFQ34612127-0065A0AF-7040-40CA-87F1-835C75614171Q34680930-562C1F3D-3DA2-41A4-8CBC-D9039F2C8699Q34799858-602FDE68-567A-4452-995B-3C2261BF440CQ34828645-11C3DBC9-4884-42C3-9F43-297DA2D95881Q34988147-BE10C6F9-B49F-4D53-AA15-BE41F8E2AC7DQ34994530-9645C8F4-5D66-475D-876F-0B5024042593Q35028770-9881C2A2-99FF-41BD-B65D-ADB05AB0A81F
P2860
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@en
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@nl
type
label
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@en
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@nl
prefLabel
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@en
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@nl
P2093
P1433
P1476
EAU guidelines on non-muscle-i ...... the bladder, the 2011 update.
@en
P2093
Andreas Böhle
Eero Kaasinen
European Association of Urology (EAU)
Juan Palou-Redorta
Marko Babjuk
Morgan Rouprêt
Richard Sylvester
Willem Oosterlinck
P304
P356
10.1016/J.EURURO.2011.03.017
P407
P577
2011-03-22T00:00:00Z